VTGN VistaGen Therapeutics Forecast, Technical & Fundamental Analysis
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia... Show more
VTGN is expected to report earnings to fall 44.44% to -25 cents per share on August 06
Q2'26
Est.
$-0.25
Q4'25
Beat
by $0.28
Q3'25
Missed
by $0.01
Q2'25
Beat
by $0.14
Q1'25
Beat
by $0.41
The last earnings report on February 12 showed earnings per share of -44 cents, beating the estimate of -73 cents. With 847.19K shares outstanding, the current market capitalization sits at 9.29M.
A.I. Advisor
published General Information
General Information
a developer of embryonic stem cells for drug discovery and development
A.I.dvisor indicates that over the last year, VTGN has been loosely correlated with MENS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VTGN jumps, then MENS could also see price increases.
Momentum Indicator for VTGN turns negative, indicating new downward trend
VTGN saw its Momentum Indicator move below the 0 level on July 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In of the 90 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
VTGN moved below its 50-day moving average on June 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VTGN crossed bearishly below the 50-day moving average on July 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for VTGN just turned positive on July 22, 2026. Looking at past instances where VTGN's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VTGN advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .
VTGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.262) is normal, around the industry mean (19.146). P/E Ratio (0.000) is within average values for comparable stocks, (37.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.793) is also within normal values, averaging (392.866).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VTGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
